A high intake of trans fatty acids has little effect on markers of inflammation and oxidative stress in humans

Journal of Nutrition

Volumn 141, Issue 9, 2011, Pages 1673-1678

  Smit, Liesbeth A ^a   Katan, Martijn B ^a   Wanders, Anne J ^b   Basu, Samar ^c   Brouwer, Ingeborg A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; C REACTIVE PROTEIN; CARBOHYDRATE; CONJUGATED LINOLEIC ACID; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAT; INTERLEUKIN 6; ISOPROSTANE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOUNSATURATED FATTY ACID; OLEIC ACID; POLYUNSATURATED FATTY ACID; PROTEIN; TRANS FATTY ACID; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FAT INTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LIPID COMPOSITION; LIPID PEROXIDATION; MALE; MOLECULAR MECHANICS; NORMAL HUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; URINE LEVEL;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; DIETARY FATS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; TRANS FATTY ACIDS; YOUNG ADULT;

EID: 80052582848     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.110.134668     Document Type: Article

References (51)

1. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354:1601-13.
2. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009;63 Suppl 2:S5-21.
3. Mensink RP, Katan MB. Effect of dietary trans fatty acids on highdensity and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323:439-45.
4. Katan MB. Regulation of trans fats: the gap, the Polder, and McDonald's French fries. Atheroscler Suppl. 2006;7:63-6.
5. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655-73.
6. Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology. 2007;58:513-22.
7. Wallace SK, Mozaffarian D. Trans-fatty acids and nonlipid risk factors. Curr Atheroscler Rep. 2009;11:423-33.
8. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38.
9. Mozaffarian D, Pischon T, Hankinson SE, Rifai N, Joshipura K, Willett WC, Rimm EB. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr. 2004;79:606-12.
10. Lopez-Garcia E, Schulze MB, Meigs JB, Manson JE, Rifai N, Stampfer MJ, Willett WC, Hu FB. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr. 2005;135:562-6.
11. Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC. Trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr. 2004;80:1521-5.
12. Mozaffarian D. Trans fatty acids: effects on systemic inflammation and endothelial function. Atheroscler Suppl. 2006;7:29-32.
13. Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res. 2002;43:445-52.
14. Baer DJ, Judd JT, Clevidence BA, Tracy RP. Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. Am J Clin Nutr. 2004;79:969-73.
15. Lichtenstein AH, Erkkila AT, Lamarche B, Schwab US, Jalbert SM, Ausman LM. Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis. 2003;171:97-107.
16. Gross M, Steffes M, Jacobs DR Jr, Yu X, Lewis L, Lewis CE, Loria CM. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem. 2005;51:125-31.
17. Basu S, Smedman A, Vessby B. Conjugated linoleic acid induces lipid peroxidation in humans. FEBS Lett. 2000;468:33-6.
18. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383-7.
19. Young IS. Oxidative stress and vascular disease: insights from isoprostane measurement. Clin Chem. 2005;51:14-5.
20. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998;98:2822-8.
21. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-203.
22. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288:2008-14.
23. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, Gutzki FM, Berger J, Frolich JC, Boger RH. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation. 2004;109:843-8.
24. Cassagno N, Palos-Pinto A, Costet P, Breilh D, Darmon M, Berard AM. Low amounts of trans 18:1 fatty acids elevate plasma triacylglycerols but not cholesterol and alter the cellular defence to oxidative stress in mice. Br J Nutr. 2005;94:346-52.
25. Wanders AJ, Brouwer IA, Siebelink E, Katan MB. Effect of a high intake of conjugated linoleic acid on lipoprotein levels in healthy human subjects. PLoS ONE. 2010;5:e9000.
26. Ramakers JD, Plat J, Sebedio JL, Mensink RP. Effects of the individual isomers cis-9,trans-11 vs. trans-10,cis-12 of conjugated linoleic acid (CLA) on inflammation parameters in moderately overweight subjects with LDL-phenotype B. Lipids. 2005;40:909-18.
27. Steck SE, Chalecki AM, Miller P, Conway J, Austin GL, Hardin JW, Albright CD, Thuillier P. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. J Nutr. 2007; 137:1188-93.
28. Smedman A, Basu S, Jovinge S, Fredrikson GN, Vessby B. Conjugated linoleic acid increased C-reactive protein in human subjects. Br J Nutr. 2005;94:791-5.
29. Tholstrup T, Raff M, Straarup EM, Lund P, Basu S, Bruun JM. An oil mixture with trans-10, cis-12 conjugated linoleic acid increases markers of inflammation and in vivo lipid peroxidation compared with cis-9, trans-11 conjugated linoleic acid in postmenopausal women. J Nutr. 2008;138:1445-51.
30. Feunekes GI, Van Staveren WA, De Vries JH, Burema J, Hautvast JG. Relative and biomarker-based validity of a food-frequency questionnaire estimating intake of fats and cholesterol. Am J Clin Nutr. 1993; 58:489-96.
31. Mitchikpe ECS, Dossa RAM, Ategbo EAD, van Raaij JMA, Hulshof PJM, Kok FJ. The supply of bioavailable iron and zinc may be affected by phytate in Beninese children. J Food Compost Anal. 2008;21:17-25.
32. Folch JL, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497-509.
33. Metcalfe LD, Schmitz AA, Pekka JR. Rapid preparation of fatty acid esters from lipids for gas chromatographic analysis. Anal Chem. 1966;38:514.
34. Basu S. Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids. 1998;58:319-25.
35. Zock PL, Mensink RP, Harryvan J, de Vries JH, Katan MB. Fatty acids in serum cholesteryl esters as quantitative biomarkers of dietary intake in humans. Am J Epidemiol. 1997;145:1114-22.
36. Brouwer IA, Wanders AJ, Katan MB. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans-a quantitative review. PLoS ONE. 2010;5:e9434.
37. Tomey KM, Sowers MR, Li X, McConnell DS, Crawford S, Gold EB, Lasley B, Randolph JF Jr. Dietary fat subgroups, zinc, and vegetable components are related to urine F2a-isoprostane concentration, a measure of oxidative stress, in midlife women. J Nutr. 2007;137:2412-9.
38. Basu S, Riserus U, Turpeinen A, Vessby B. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clin Sci (Lond). 2000;99:511-6.
39. Basu S. The enigma of in vivo oxidative stress assessment: isoprostanes as an emerging target. Scand J Food Nutr. 2007;51:48-61.
40. Iannone A, Petroni A,Murru E, Cordeddu L, Carta G,Melis MP, Bergamini S, Casa LD, Cappiello L, Carissimi R, et al. Impairment of 8-iso-PGF(2ALPHA) isoprostane metabolism by dietary conjugated linoleic acid (CLA). Prostaglandins Leukot Essent Fatty Acids. 2009;80:279-87.
41. Riserus U, Basu S, Jovinge S, Fredrikson GN, Arnlov J, Vessby B. Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Circulation. 2002;106:1925-9.
42. Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. Conjugated linoleic acid impairs endothelial function. Arterioscler Thromb Vasc Biol. 2006;26:307-12.
43. Santos-Zago LF, Botelho AP, de Oliveira AC. Supplementation with commercial mixtures of conjugated linoleic acid in association with vitamin E and the process of lipid autoxidation in rats. Lipids. 2007; 42:845-54.
44. Arbones-Mainar JM, Navarro MA, Guzman MA, Arnal C, Surra JC, Acin S, Carnicer R, Osada J, Roche HM. Selective effect of conjugated linoleic acid isomers on atherosclerotic lesion development in apolipoprotein E knockout mice. Atherosclerosis. 2006;189:318-27.
45. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486-91.
46. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95:C9-16; discussion C38-40.
47. Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 2009;19:521-4.
48. Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J. 2003;24:2161-3.
49. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293:1338-47.
50. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:56-65.
51. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, Roussel AM, Favier A, Briancon S. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164:2335-42.